The stock market is rigged in favor of big Wall Street firms with deep pockets and scores of number-crunching analysts.
I call these stock market insiders “front traders.”
Before now, you may never have heard about the tiny companies that I’m going to uncover today…
But using tools that most of us don’t have, front traders have just dropped millions of dollars on each of them.
Some of these stocks might even make millionaires out of traders.
No, it’s not fair at all.
But you’ve got a major leg up in the stock market.
That’s right…
Along with my own crack team of analysts, I follow these front traders with hawk eyes.
And my mission is simple: Identify front traders’ secretive purchases and reveal their strategies so that everyday investors like YOU to get a fair shake at real profits in the market.
Here’s what I just saw in the markets…
— RECOMMENDED —
MENSA considers him a genius!
Find out how this former landscaper makes millions trading the trickiest market
This Front Trader’s Going All In
Ever heard of Karyopharm Therapeutics (KPTI)?
If you haven’t, you aren’t alone.
But this little-known cancer drugmaker was the target of an eye-popping front trade.
Led by billionaire front trader Steven Cohen, Point72 Management just reported a 1.9 million share purchase of KPTI.
That more than doubled the fund’s stake in the tiny healthcare company.
Here’s why this trade is such a big deal…
The stock is down more than 80% over the last six months. And the company is due to report fourth quarter earnings later this month.
Doubling up on this position is a sign of deep conviction in a company that has yet to turn a profit.
Steven Cohen is known for taking big risks for big returns — but he’s no dummy.
This purchase was likely made after meticulous analysis using information that’s out of reach for most investors. So it’s fair to say that he knows something here.
His front trading firm isn’t the only one to step into the most aggressive stocks on the market…
— RECOMMENDED —
FREE STOCK TRADING WEBINAR
Experienced Biotech stock investor, Kyle Dennis, will be showing you 3 easy-to-follow steps that you’re going to want in your playbook & he’s got the numbers to prove it!
A Front Trading Legend Eyes Brand-Name Profits at a Generic Price
Legendary hedge fund D. E. SHAW & CO, L.P. bought 664,152 shares of biotech firm Lannett Co. (LCI).
The firm boosted its stake in the company by more than a third.
If you’re unfamiliar with Lannett, it produces generic versions of some of the most popular brand-name drugs on the market.
The list includes Lipitor, Concerta, Prilosec… and many more.
Now, D.E. Shaw’s purchase may not seem like many shares. But this small buy is likely the start of a much larger position.
Lannett is a $200 million company with an average daily volume of about 1.5 million shares.
So in order for a front trader to get the best price for its shares, it has to buy up stock in “small” chunks.
In addition, since last August… insiders have purchased more than $469,000 in shares with their own money.
The big buys from front traders and insiders together tell us positive news is likely on the way for LCI.
And if that’s the case, these early risk-takers will be rewarded handsomely with profits down the stretch.
Speaking of early moving front traders, these firms wasted no time piling to this newly-public drugmaker…
— RECOMMENDED —
FREE PENNY STOCKS WEBINAR
How You Can Get BIG Gains from a Small Account… FAST!
Led Higher By Front Traders, Another Biotech Soars After Recent IPO
Harpoon Therapeutics (HARP), which focuses on lung cancer drugs, went public nearly a month ago.
And three front traders jumped right into the stock, sending its shares sharply higher after it listed.
Well, the same scenario might be playing out again on a brand-new small cap healthcare stock…
AVEDRO Inc. (AVDR) makes special medical devices to help doctors treat eye diseases.
The company went public on Feb. 14, and two big-time front traders reported a couple of large buys.
Orbimed Advisors bought 4.3 million shares, taking a sizeable 25% stake in AVEDRO.
And venture capital firm Healthquest Partners bought 1.4 million shares — a position worth just over 8% of outstanding shares.
AVDR is down modestly from its trading debut, but this speculative name is worth watching.
After all, when multiple front traders jump into a stock at the same time… other front traders often follow out of fear of missing out on a big profit.
That’s what just happened to Harpoon’s stock. And HARP’s early pop is EXACTLY why we want to step into stocks with clusters of front trades — before the rest of the Street piles in.
These trades are too speculative right now to recommend as official plays.
But I’ll continue to watch these names as they become more solid investments, so stay tuned!
Front traders don’t always pick winners.
But armed with expensive tools and infinite manpower… they are right more often than not about where — and when — to invest.
And here at The Daily Edge, you’ve finally got the same advantage that they do…
We’re watching the smart money’s moves closely and delivering you some of their favorite trades so you can enjoy life-changing profits as well.